An Open-Label Study to Evaluate the Absorption, Distribution, Metabolism, and Excretion of TD-9855 Following a Single Oral Dose Containing Approximately 100 µCi [14C]-Labeled TD-9855 (20 mg) in Healthy Subjects
Phase of Trial: Phase I
Latest Information Update: 16 Oct 2017
At a glance
- Drugs TD 9855 (Primary)
- Indications Attention-deficit hyperactivity disorder; Fibromyalgia
- Focus Pharmacokinetics
- Sponsors Theravance
- 16 Oct 2017 Last checked against ClinicalTrials.gov record.
- 12 May 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
- 12 Nov 2013 Status changed from not yet recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.